Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of SyB C-1101 (Rigosertib) in MDS
NCT02014051Phase 1Completed
- Sponsor
- SymBio Pharmaceuticals
- Start
- Mar 2013
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rigosertib in myelodysplastic syndrome (MDS) (2 arms), sponsored by SymBio Pharmaceuticals. Primary endpoints: Adverse Events up to 18 weeks and Number of Participants Who Experienced Dose-limiting Toxicities up to 21 days. Started Mar 2013; status: completed.
02
Drugs
rigosertib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02014051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02014051.